To reduce the incidence of higher-grade CRS with prophylactic administration of tocilizumab during teclistamab treatment, specifically targeting patients at high risk for severe CRS.
Key Findings:
CRS occurred in 26.3% of the prophylactic cohort compared to 73.3% in the non-prophylactic cohort, indicating a significant reduction.
The majority of CRS events in the prophylactic cohort were grade 1, suggesting a favorable safety profile.
Prophylactic tocilizumab did not increase the incidence of grade 3 or 4 neutropenia, maintaining treatment tolerability.
Interpretation:
Prophylactic tocilizumab significantly reduced the incidence and severity of CRS in patients receiving teclistamab, suggesting it can be safely integrated into outpatient treatment protocols without compromising efficacy.
Limitations:
Short follow-up period of 113 days may not capture long-term outcomes.
Small sample size and single-center design may limit generalizability and introduce bias.
Conclusion:
Early incorporation of prophylactic tocilizumab effectively prevents severe CRS, enhancing the safety of outpatient teclistamab administration and warranting further investigation in larger, multi-center studies.
by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
